Trial Profile

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MC 510050 (Primary) ; Cyclophosphamide; Fludarabine
Indications B-cell leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use

06 Jun 2023 Results assessing (n=19) safety and durable disease remission in R/R B-acute lymphoblastic leukaemia presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
06 Jun 2023 Preliminary results(As of May 2022, n=13) assessing safety and efficacy MC-1-50 for treatment of r/r NHL presented at the 59th Annual Meeting of the American Society of Clinical Oncology
16 Apr 2023 Planned End Date changed from 1 Jul 2022 to 1 Jul 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com